Headlines about Allscripts Healthcare Solutions (NASDAQ:MDRX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allscripts Healthcare Solutions earned a daily sentiment score of 0.20 on Accern’s scale. Accern also gave media headlines about the software maker an impact score of 46.3277608152432 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Fremantle selects Allscripts to maximise data capture, interoperability and usability (finance.yahoo.com)
- Allscripts Healthcare Solutions, Inc. (MDRX) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Financial Contrast: Allscripts Healthcare Solutions (MDRX) & Its Peers (americanbankingnews.com)
- $430.10 Million in Sales Expected for Allscripts Healthcare Solutions, Inc. (MDRX) This Quarter (americanbankingnews.com)
- Allscripts to release third quarter 2017 financial results November 2 – GlobeNewswire (press release) (globenewswire.com)
Several equities analysts recently commented on MDRX shares. Jefferies Group LLC set a $17.00 target price on Allscripts Healthcare Solutions and gave the company a “buy” rating in a report on Friday, August 25th. Maxim Group reissued a “buy” rating and issued a $16.00 target price on shares of Allscripts Healthcare Solutions in a report on Friday, August 4th. Cantor Fitzgerald reissued a “buy” rating and issued a $17.00 target price (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a report on Monday, August 14th. Dougherty & Co restated a “buy” rating and issued a $16.00 price objective (up previously from $15.00) on shares of Allscripts Healthcare Solutions in a research note on Tuesday, October 3rd. Finally, Zacks Investment Research upgraded shares of Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. Allscripts Healthcare Solutions currently has an average rating of “Hold” and an average price target of $15.19.
Allscripts Healthcare Solutions (NASDAQ MDRX) opened at 13.98 on Wednesday. The company’s 50-day moving average is $13.62 and its 200 day moving average is $12.63. Allscripts Healthcare Solutions has a 12-month low of $9.80 and a 12-month high of $14.45. The stock’s market capitalization is $2.52 billion.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last issued its quarterly earnings results on Thursday, August 3rd. The software maker reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.04). The company had revenue of $426.10 million during the quarter, compared to analyst estimates of $424.94 million. Allscripts Healthcare Solutions had a positive return on equity of 5.97% and a negative net margin of 11.54%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.14 earnings per share. On average, analysts predict that Allscripts Healthcare Solutions will post $0.62 EPS for the current year.
In other news, EVP Brian Farley sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $13.52, for a total value of $67,600.00. Following the completion of the sale, the executive vice president now directly owns 196,607 shares of the company’s stock, valued at approximately $2,658,126.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Paul Black sold 15,000 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $13.52, for a total transaction of $202,800.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,000 shares of company stock valued at $473,800. Company insiders own 0.75% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/11/allscripts-healthcare-solutions-mdrx-earns-news-impact-rating-of-0-20.html.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc (Allscripts) delivers information technology (IT) solutions and services to help healthcare organizations. The Company operates through three segments: Clinical and Financial Solutions, Population Health, and Netsmart. The Clinical and Financial Solutions segment includes the sale of integrated clinical software applications and financial and information solutions.
Receive News & Ratings for Allscripts Healthcare Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.